These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 29683280)

  • 21. Hidradenitis suppurativa in association with keratitis-ichthyosis-deafness syndrome treated with adalimumab.
    Song YM; Kim YS; Lee JH; Park YM; Lee JY
    J Dermatol; 2018 Sep; 45(9):e262-e263. PubMed ID: 29570225
    [No Abstract]   [Full Text] [Related]  

  • 22. Population Pharmacokinetics and Immunogenicity of Adalimumab in Adult Patients with Moderate-to-Severe Hidradenitis Suppurativa.
    Nader A; Beck D; Noertersheuser P; Williams D; Mostafa N
    Clin Pharmacokinet; 2017 Sep; 56(9):1091-1102. PubMed ID: 28066879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab.
    Harde V; Mrowietz U
    J Dtsch Dermatol Ges; 2009 Feb; 7(2):139-41. PubMed ID: 19371236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study.
    Zouboulis CC; Okun MM; Prens EP; Gniadecki R; Foley PA; Lynde C; Weisman J; Gu Y; Williams DA; Jemec GBE
    J Am Acad Dermatol; 2019 Jan; 80(1):60-69.e2. PubMed ID: 29860040
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab.
    Caposiena Caro RD; Cannizzaro MV; Tartaglia C; Bianchi L
    Clin Exp Dermatol; 2020 Jun; 45(4):438-444. PubMed ID: 31630436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic approach to Crohn disease: possible parallels with hidradenitis suppurativa.
    González Lama Y; Marín-Jiménez I
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():2-7. PubMed ID: 28081765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of adalimumab on T-helper-17 lymphocyte- and neutrophil-related inflammatory serum markers in patients with moderate-to-severe hidradenitis suppurativa.
    Jiménez-Gallo D; de la Varga-Martínez R; Ossorio-García L; Collantes-Rodríguez C; Rodríguez C; Linares-Barrios M
    Cytokine; 2018 Mar; 103():20-24. PubMed ID: 29289722
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term successful adalimumab therapy in severe hidradenitis suppurativa.
    Blanco R; Martínez-Taboada VM; Villa I; González-Vela MC; Fernández-Llaca H; Agudo M; González-López MA
    Arch Dermatol; 2009 May; 145(5):580-4. PubMed ID: 19451504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of hidradenitis suppurativa in a patient treated with ustekinumab for her psoriasis: A potential paradoxical reaction?
    Gkini MA; Bewley AP
    Dermatol Ther; 2018 Nov; 31(6):e12742. PubMed ID: 30221819
    [No Abstract]   [Full Text] [Related]  

  • 30. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte-macrophage colony-stimulating factor for perianal hidradenitis suppurativa: report of a case.
    Sharon-Guidetti A; Ziv Y; Kummer E; Yogev R; Halevy A
    Dis Colon Rectum; 2006 May; 49(5):682-4. PubMed ID: 16435164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hidradenitis suppurativa: Current and emerging treatments.
    Goldburg SR; Strober BE; Payette MJ
    J Am Acad Dermatol; 2020 May; 82(5):1061-1082. PubMed ID: 31604100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram JR; Burton T
    Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
    [No Abstract]   [Full Text] [Related]  

  • 35. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.
    Ryan C; Sobell JM; Leonardi CL; Lynde CW; Karunaratne M; Valdecantos WC; Hendrickson BA
    Am J Clin Dermatol; 2018 Jun; 19(3):437-447. PubMed ID: 29380251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steatocystoma multiplex suppurativa associated with hidradenitis suppurativa successfully treated with adalimumab.
    Atzori L; Zanniello R; Pilloni L; Rongioletti F
    J Eur Acad Dermatol Venereol; 2019 Oct; 33 Suppl 6():42-44. PubMed ID: 31535759
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
    Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adalimumab versus Rifampicin Plus Clindamycin for the Treatment of Moderate to Severe Hidradenitis Suppurativa: A Retrospective Study.
    Marasca C; Annunziata MC; Villani A; Volpe S; Marasca D; Fabbrocini G
    J Drugs Dermatol; 2019 May; 18(5):437-438. PubMed ID: 31141853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emerging drugs for the treatment of hidradenitis suppurativa.
    Folkes AS; Hawatmeh FZ; Wong A; Kerdel FA
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):201-211. PubMed ID: 32667213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Features of Patients With Crohn's Disease and Hidradenitis Suppurativa.
    Kamal N; Cohen BL; Buche S; Delaporte E; Colombel JF
    Clin Gastroenterol Hepatol; 2016 Jan; 14(1):71-9. PubMed ID: 25956836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.